A new drug, MDNA113, is a potential game-changer for prostate cancer patients and those battling other aggressive tumors. This first-in-class immunotherapy targets a protein often found in high levels on cancer cells, offering a precise and powerful approach to treatment.

Unlike traditional immunotherapies, which have struggled to make headway against prostate cancer’s defenses, MDNA113 combines two potent weapons: an anti-PD1 antibody to disable the tumor’s ability to hide from the immune system and an IL-2 Superkine to supercharge immune cells. What makes this drug unique is its laser-like focus on IL-13Rα2, a receptor overexpressed not only in aggressive prostate cancers, particularly castration-resistant forms, but also in other hard-to-treat tumors like pancreatic and ovarian cancers. This multi-tumor potential broadens its promise, positioning MDNA113 as a versatile tool in the fight against cancer.

The drug’s design is as clever as it is effective. MDNA113 is “masked” to prevent it from activating until it reaches the tumor, where enzymes in the cancer’s microenvironment unlock its full potential. This targeted approach, showcased at the 2025 American Association for Cancer Research meeting, minimizes the toxic side effects often seen with IL-2 therapies, offering hope for safer, more effective treatment. Preclinical studies have shown MDNA113 accumulating in IL-13Rα2-rich tumors, sparking robust immune responses in models of challenging cancers, including those with low immune activity like prostate cancer.

For prostate cancer patients, the stakes are high. Current options, like the personalized vaccine sipuleucel-T, extend life but don’t cure, and immune checkpoint inhibitors work only for a small subset of patients with specific genetic profiles. MDNA113’s ability to zero in on IL-13Rα2, a marker tied to poor outcomes in castration-resistant prostate cancer, could address this gap. Unlike sipuleucel-T, which requires complex cell processing, MDNA113 is an off-the-shelf therapy, making it more accessible and scalable.

Source.